A.
Monotherapy with the most potent drug.
✓
B.
Intermittent therapy to reduce drug burden.
✓
C.
Combination therapy with drugs from different classes.
✓
D.
High-dose therapy for a short duration.
✓
A.
Inhibiting TNF-alpha.
✓
B.
Blocking cyclooxygenase enzymes.
✓
C.
Inhibiting dihydrofolate reductase, leading to folate depletion.
✓
D.
Stimulating B-cell proliferation.
✓
B.
Infusion-related reactions (e.g., fever, chills, rigors).
✓
A.
Inhibiting vitamin K-dependent clotting factors.
✓
B.
Selectively inhibiting Factor Xa.
✓
C.
Directly inhibiting thrombin.
✓
D.
Activating protein C.
✓
A.
Equianalgesic dosing.
✓
B.
Pharmacodynamic tolerance.
✓
C.
Drug-receptor binding affinity.
✓
D.
First-pass metabolism.
✓
A.
Severe hypertension.
✓
C.
Transient asystole/bradycardia.
✓
D.
Profound hypoglycemia.
✓
A.
Hepatotoxicity and cardiotoxicity.
✓
B.
Nephrotoxicity and ototoxicity.
✓
C.
Myelosuppression and dermatological reactions.
✓
D.
Hyperglycemia and hypokalemia.
✓
